Infectious Disease

Lovelace Biomedical’s infectious disease program is actively developing and refining enhanced in vitro and in vivo capabilities to improve our understanding of the host response to infection, as well as new and enhanced systems to evaluate medical countermeasures against recurring and emerging biological threats. These capabilities serve to positively impact human health through the evaluation of vaccines, therapeutics and other medical countermeasures against bacterial, viral, fungal and toxin exposures.

Capabilities include:

  • Production of highly characterized viral, bacterial and fungal challenge stocks for use in evaluation of medical treatments and countermeasures
  • Viral and bacterial neutralization and clearance assays using standard titer techniques, serological assays, as well as PCR-based and immunofluorescence methods
  • High-resolution histopathology, morphometry, in situ hybridization, and immunohistochemistry with epithelial cell markers for distinct lung cell populations

Infectious Disease Fact Sheet : Download

Infectious Disease

Lovelace Biomedical is a globally recognized leader in treatment and regulation against infectious diseases. Our team conducts a full range of infectious disease studies under both Good Laboratory Practice (GLP) or non-GLP guidelines. We have the capability of exploring a variety of infectious diseases with our ABSL 1, 2, 3 & 3+ facilities. We integrate quality, leading-edge expertise, and an experienced and well trained staff to meet study goals.

Infectious Disease Models

Our infectious disease models are state of the art, allowing us to both explore the pathogenesis of disease as well as applying them to develop novel prevention and therapeutic strategies. Our professional staff has a vast experience in programs which include both In Vivo and In Vitro components. We use these methods, and other capabilities in order to fully understand the host’s response to infection, and also evaluate new medical countermeasures against recurring and emerging biological threats. We strive to serve human health through the evaluation of vaccines, therapeutics and other countermeasures targeting infectious diseases.

Capabilities Include

  • Production of highly characterized viral, bacterial and fungal challenge stocks for use in evaluation of medical treatments and countermeasures
  • Viral and bacterial neutralization and clearance assays using standard titer techniques, serological assays, as well as PCR-based and immunofluorescence methods
  • High-resolution histopathology, morphometry, in situ hybridization, and immunohistochemistry with epithelial cell markers for distinct lung cell populations
threelakhs

300,000

square feet of laboratory space

500+ staff

centralized in Albuquerque, New Mexico

fifty

50+

cross-trained research technicians

Years

70+ Years

of toxicology experience

Infectious Disease Models